{'fraction_non_alphanumeric': 0.024078254326561323, 'fraction_numerical': 0.007524454477050414, 'mean_word_length': 5.244131455399061, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinical and laboratory effects of long‐term administration of hydroxyurea to patients with sickle‐cell/β‐thalassaemia

Hydroxyurea (HU), a widely used cytostatic, has been given over a long period of time to 14 adult Caucasian compound heterozygotes for βs and various β‐thalassaemia genes. All patients had severe pain crises and other complications prior to receiving the drug. After 4‐8 weeks on high ‘sub‐toxic’doses of HU all patients responded with a multifold increase of fetal haemoglobin (HbF) and a marked increase of MCV and MCH; they also felt significantly better and ceased having pains or other complaints. Haematological toxicity was minimal and rapidly reversible. Follow‐up of the patients has now exceeded 100 weeks and goes up to 180 weeks in two of them. Pain crises have never recurred. Maintenance of high levels of HBF requires continuous administration of high doses of HU; whenever the latter were decrease in various attempts to avoid potential long‐term toxicity, the observed changes gradually faded. The effect of HU in HbS/β‐thalassaemia may be better than that reported for homozygous HbS disease because the synthesized λ‐chains not only inhibit the sickling process but they also neutralize the noxious effects of the excess α‐chains and cut down the ineffective erythropoiesis of the patients.